Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Our Center's mission is to advance precision cancer medicine by developing new technologies for the analysis of cancer genomes, and to provide basic, translational, and clinical investigators with access to these technologies.
The Center provides DNA, RNA, and amplicon sequencing, as well as bioinformatics support and assistance in experimental design, new technology development, and help with challenging samples.
CCGD services provide access to the newest genome technologies for investigators and clinicians at Dana-Farber and beyond. Contact us to start collaborating.
Profile: A personalized medicine cancer research study
The Center for Cancer Genome Discovery (CCGD) is the research and development group within the Precision Cancer Medicine effort at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Boston Children’s Hospital. Our mission is to develop, evaluate, and implement novel technologies at the forefront of genome science in order to detect genetic alterations in tumors within the context of Precision Cancer Medicine.
Integrative RNA Sequencing
RNAseq (targeted or whole transcriptome) can add functionality to DNAseq by quantifying expression of the mutant allele or downstream genes in the pathway.
New patterned flow cell provides even spacing of sequencing clusters to deliver significant increases in sequencing reads and total output of the system.
Copy number variants are now being identified using RobustCNV, a new algorithm developed at the Center for Cancer Genome Discovery (CCGD).
Customize Your Sequencing
Design, mix, and match any genomic region in a custom baitset – targeted panels, exome+, translocations, promoters, enhancers. CCGD will take care of it.
Read about our one-day symposium, Genomic Approaches towards Precision Cancer Medicine, to be held March 3, 2017, in Dana-Farber's Jimmy Fund Auditorium, Boston, MA
Meet Our Directors, Staff, Bioinformatics Team, and Faculty
CCGD: Aaron ThornerProfile: Elizabeth GarciaBioinformatics: Matthew Ducar
For general questions:617-582-7253 orAaron_Thorner@dfci.harvard.edu